Rebekah Hendry, NP
Gerontology · Bossier City, LANPI 1407520620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 24.3% of the total. Among gerontology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$466
- Merck$266
- Insmed, Inc.$249
- plus $1K from 16 others
What the payments were for
- Food & beverage$6,11195%
- Education$2915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $1,555 |
| GSK | 63 | $1,334 |
| Actelion Pharmaceuticals US, Inc. | 45 | $1,073 |
| Boehringer Ingelheim | 22 | $466 |
| Merck | 13 | $266 |
| Insmed, Inc. | 11 | $249 |
| Inogen, Inc. | 20 | $209 |
| Bayer | 8 | $178 |
| United Therapeutics Corporation | 7 | $175 |
| Sanofi | 6 | $131 |
| Regeneron Healthcare Solutions, Inc. | 6 | $129 |
| Paratek Pharmaceuticals, Inc. | 5 | $103 |
| Amgen | 5 | $102 |
| Mylan Specialty L.p. | 4 | $95 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| Baxter Healthcare | 3 | $77 |
| Electromed, Inc. | 4 | $65 |
| Shionogi Inc | 2 | $37 |
| Inari Medical, Inc. | 1 | $25 |
| Pfizer | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,402 in reported general payments places this provider in the 95th percentile of 64 gerontology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 463 | $410,412 |
| OfevNintedanib Esylate | 19 | $247,110 |
| TezspireTezepelumab-Ekko | 13 | $54,213 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $28,800 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $24,170 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $23,116 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $22,372 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $22,164 |
| Spiriva RespimatTiotropium Bromide | 32 | $17,637 |
| Atrovent HfaIpratropium Bromide | 12 | $12,232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 248 | $8,893 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,892 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,873 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $4,917 |
| Ventolin HfaAlbuterol Sulfate | 38 | $2,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,334 | $461,376533 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $466 | $295,75589 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,555 | $84,45773 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 gerontology providers in Louisiana.
Other gerontology in Bossier City
- Jodie HarrisonSlidell$12K
- Whitney StevensSlidell$10K
- Jessica GaubertBaton Rouge$6K
- Kathy BernsteinNew Orleans$6K
- Katrina GipsonMonroe$6K
- Jennifer HarveySlidell$5K
- Maureen PoeSulphur$5K
- Cynthia TurnerMonroe$5K
- Victoria ChapmanMinden$4K
- Brandt SandersLafayette$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.